Aquestive Therapeutics elects Richard J. Daly to board, expanding directorships from seven to eight

Aquestive Therapeutics, Inc.

Richard J. Daly elected as Class I director effective October 14, 2026, with term expiring at the 2028 Annual Meeting of Stockholders.
Board size increased from seven to eight directors; seven of eight are independent under Nasdaq listing standards.
Daly receives an initial award of 57,000 stock options under the 2018 Equity Incentive Plan, vesting in annual one-third increments.
Option grant date is the second full trading day after the next quarterly or annual earnings release, with exercise price equal to that day's closing price.
CEO Daniel Barber cited Daly's commercial leadership at AstraZeneca, Takeda and Catalyst as valuable for a potential Anaphylm launch.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.